B-type natriuretic peptide measurement in primary care; Magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's Screening to Prevent Heart Failure) study

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 4, 2011, Pages 719-728

  Conlon, Carmel M ^a,b   Dawkins, Ian ^a   O'Loughlin, Christina ^a   Gibson, Denise ^a   Kelleher, Cecily C ^b   Ledwidge, Mark ^a   McDonald, Kenneth ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

blockers; biomarker; epidemiology; heart rate; reference chart

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION RESPONSE; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PRIMARY HEALTH CARE; REFERENCE VALUES; RISK FACTORS;

EID: 79954457548     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.098     Document Type: Article

References (42)

1. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dys-function. J Am Coll Cardiol 2006;17:345-53. (Pubitemid 43063253)
2. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natri-uretic peptide in the evaluation of left ventricular diastolic func-tion: comparison with tissue Doppler imaging recordings. Am Heart J 2004;148:895-902.
3. McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, et al. The prognostic value ofN-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 2010;55:2140-7.
4. Conlon C, O'Loughlin C, McGrath M, Murphy N, Ledwidge M, McDonald K. The STOP-HF study. Screening TO Prevent Heart Failure: design and methodology. Eur J Heart Fail 2006;5(Suppl):30.
5. Conlon C, O'Loughlin C, Murphy N, Kelleher CC, Ledwidge M, McDonald K. Predictors of higher BNP levels in a popu-lation with cardiovascular risk factors. Eur Heart J 2007;28 (Suppl):783-4.
6. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT Blood Press Monit 2003;3:127-33. (Pubitemid 37034568)
7. Sykes E, Karcher RE, Eisenstadt J, Tushman DA, Balasubra-maniam M, Gusway J, et al. Analytical relationships among Biosite, Bayer, and Roche methods for BNP and NTproBNP. Am J Clin Pathol 2005;123:584-90. (Pubitemid 40418554)
8. Panz VR, Raal FJ, Paiker J, Immelman R, Miles H. Perform-ance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc J S Afr 2005;16: 112-7. (Pubitemid 41103512)
9. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002;90:254-8. (Pubitemid 34804560)
10. Alehagen U, Goetze JP, Dahlstrom U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its pre-cursor (Nt-proBNP) in the elderly Clin Chim Acta 2007;382: 8-14. (Pubitemid 46782725)
11. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
12. Radovanovic M, Vasiljevic Z, Radovanovic N, Marinkovic J, Beleslin B, Mitrovic P, et al. B-type natriuretic peptide in out-patients after myocardial infarction: optimized cut-off value for incident heart failure prediction. Peptides 2010:6:30.
13. O'Hanlon R, O'Shea P, Ledwidge M, O'Loughlin C, Lange S, Conlon C, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:50-5. (Pubitemid 46330833)
14. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Bau-mann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003;89:745-51. (Pubitemid 36760633)
15. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bai-ley KR, Burnett JC Jr. Plasma brain natriuretic peptide concen-tration: impact of age and gender. J Am Coll Cardiol 2002;40: 976-82. (Pubitemid 34994995)
16. Segawa T, Nakamura M, Itai K, Onoda T, Okayama A, Hira-mori K. Plasma B-type natriuretic peptide levels and risk fac-tors for congestive heart failure in a Japanese general population. Int Heart J 2005;46:465-75.
17. Weber M, Dill T, Arnold R, Rau M, Ekinci O, Muller KD, et al. N-terminal B-type natriuretic peptide predicts extent of cor-onary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004;148:612-20. (Pubitemid 39349380)
18. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92. (Pubitemid 36705987)
19. van den Meiracker AH, Lameris TW, van de Ven LL, Boomsma F Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol. J Cardiovasc Pharmacol 2003;42:462-8. (Pubitemid 37210859)
20. Ellinor PT, Low AF, Patton KK, Shea MA, Macrae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 2005;45: 82-6. (Pubitemid 40052031)
21. Knudsen CW, Omland T, Clopton P, Westheim A, Wu AH, Duc P, et al. Impact of atrial fibrillation on the diagnostic perfor-mance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multina-tional study J Am Coll Cardiol 2005;46:838-44. (Pubitemid 41224808)
22. Jakubik P, Janota T, Widimsky J Jr, Zelinka T, Strauch B, Petrak O, et al. Impact of essential hypertension and primary aldosteronism on plasma brain natriuretic peptide concentra-tion. Blood Press 2006;15:302-7.
23. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, et al. N-terminal pro-brain natriuretic peptide predicts cardio-vascular events in patients with hypertension and left ventric-ular hypertrophy: a LIFE study J Hypertens 2004;22:1597-604. (Pubitemid 39037612)
24. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hil-debrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. J Am Med Assoc 2005;293:1609-16. (Pubitemid 40471791)
25. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005;46:118-23. (Pubitemid 40946501)
26. Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Rela-tionship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit J Am Coll Cardiol 2005;45:1667-71. (Pubitemid 40704504)
27. Tsutamoto T, Wada A, Sakai H, Ishikawa C, Tanaka T, Hayashi M, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2006;47:582-6. (Pubitemid 43170848)
28. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Car-diol 2008;101:25-8.
29. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006;47:85-90. (Pubitemid 43005169)
30. Campbell DJ, Woodward M, Chalmers JP, Colman SA, Jenkins AJ, Kemp BE, et al. Perindopril-based blood pressure-lowering therapy reduces amino-terminal-pro-B-type natriuretic peptide in individuals with cerebrovascular disease. J Hypertens 2007; 25:699-705. (Pubitemid 46213809)
31. White M, Lepage S, Lavoie J, de DS, Leblanc MH, Gossard D, et al. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glu-cose regulation in patients with symptomatic heart failure. J Card Fail 2007;13:86-94. (Pubitemid 46467388)
32. Giannessi D, Andreassi MG, Del RS, Clerico A, Colombo MG, Dini N Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 2001;24: 8-16. (Pubitemid 32166323)
33. Sayama H, Nakamura Y, Saito N, Kinoshita M. Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Coronary Artery Dis 1999;10: 537-40. (Pubitemid 30011913)
34. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant ofmyocardial fibrosis. Hypertension 2007;49:1120-7. (Pubitemid 351664300)
35. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, et al. Diagnosis of heart failure with preserved ejec-tion fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 2009;11:191-7.
36. Weber KT. From inflammation to fibrosis: a stiff stretch of highway Hypertension 2004;43:716-9. (Pubitemid 38405574)
37. Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Ray-mond K, et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third gen-eration vasodilating beta blocker. Br Heart J 1995;74:502-7.
38. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study J Am Coll Cardiol 1998;32:1839-44. (Pubitemid 29010443)
39. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003;5:599-606. (Pubitemid 38043963)
40. Lorell BH, Carabello BA. Left ventricular hypertrophy: path-ogenesis, detection, and prognosis. Circulation 2000;102: 470-9. (Pubitemid 30490688)
41. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009;338:1665.
42. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, Tuns-tall-Pedoe H, et al. Contribution of 30 Biomarkers to 10-Year Cardiovascular Risk Estimation in 2 Population Cohorts The MONICA, Risk, Genetics, Archiving, and Monograph (MOR-GAM) Biomarker Project. Circulation 2010;121:2388-97.